Dasolampanel
As of the edition of 20 October 2026, Dasolampanel is a small molecule: went quiet in 2008; acts on GRIA1, GRIA2 and GRIA3 and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2008
- Kind
- Small molecule
- Registered trials
- 1, 0 stopped early
- Disease areas
- Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| TorreyPines Therapeutics | Lead sponsor of trials | 2008 to now |